$Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial$

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial

Zhang, Pin; Sun, Tao; Zhang, Qingyuan; Yuan, Zhongyu; Jiang, Zefei; Wang, Xiao Jia; Cui, Shude; Teng, Yuee; Hu, Xi-Chun; Yang, Junlan; Pan, Hongming; Tong, Zhongsheng; Li, Huiping; Yao, Qiang; Wang, Yongsheng; Yin, Yongmei; Sun, Ping; Zheng, Hong; Cheng, Jing; Lu, Jinsong; Zhang, Baochun; Geng, Cuizhi; Liu, Jian; Peng, Roujun; Yan, Min; Zhang, Shaohua; Huang, Jian; Tang, Li; Qiu, Rongguo; Xu, Binghe

期刊名称The Lancet Oncology
作者Zhang, Pin; Sun, Tao; Zhang, Qingyuan; Yuan, Zhongyu; Jiang, Zefei; Wang, Xiao Jia; Cui, Shude; Teng, Yuee; Hu, Xi-Chun; Yang, Junlan; Pan, Hongming; Tong, Zhongsheng; Li, Huiping; Yao, Qiang; Wang, Yongsheng; Yin, Yongmei; Sun, Ping; Zheng, Hong; Cheng, Jing; Lu, Jinsong; Zhang, Baochun; Geng, Cuizhi; Liu, Jian; Peng, Roujun; Yan, Min; Zhang, Shaohua; Huang, Jian; Tang, Li; Qiu, Rongguo; Xu, Binghe
卷第18卷
期第3期
印刷ISSN1470-2045
文件大小554.29KB
发表时间2017-03
DOI10.1016/S1470-2045(17)30088-8
页码371-383

发现好书期刊，享受阅读乐趣

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial